SPEECH-PROCESSING
10.4.2024 09:03:28 CEST | Business Wire | Press release
Philips Dictation by Speech Processing Solutions, a globally leading innovator in voice technology, has announced the latest innovation in their professional cloud-based dictation and transcription solution, Philips SpeechLive. The enhancement integrates speech recognition from Nuance Dragon. This major development offers the most accurate dictation workflow, leading to new levels of efficiency for legal professionals worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410464123/en/
Philips SpeechLive with Nuance Dragon (Graphic: Business Wire)
Featuring highly precise AI-powered speech recognition integrated directly into legal workflows, this latest version of SpeechLive continuously learns for unmatched accuracy. It empowers time-constrained lawyers to create high-quality documentation while enhancing efficiency and expediting documentation completion. Additionally, assistants can access automated transcripts together with the original recordings for quick corrections, freeing them to concentrate on more meaningful tasks, ultimately boosting work satisfaction and productivity.
Dr. Thomas Brauner, CEO of Speech Processing Solutions, emphasized the significance of this partnership, stating, "The integration of Nuance Dragon into Philips SpeechLive marks a significant enhancement for legal professionals. By merging top-tier AI-powered speech recognition with the best-in-class dictation platform, we're empowering legal professionals to benefit from the best of both worlds. This unique combination will streamline their workflow and achieve new levels of efficiency and accuracy in their document creation process."
Key benefits for legal professionals include:
- Specialized Legal Vocabularies: Access tailored legal vocabularies for precise transcription and industry-specific terminology adherence.
- Custom Profiles: Personalize speech profiles to streamline workflows and boost efficiency, eliminating repetitive corrections.
- Personalized User Recognition: Nuance Dragon's adaptive learning optimizes transcription accuracy, tailoring to individual preferences.
- Enhanced Functionality: Experience streamlined features within SpeechLive, including live dictation and recording capabilities, enhancing workflow efficiency.
- Enhanced Mobility: Access SpeechLive across devices for flexible work arrangements, including PCs and mobile phones, facilitating work from any location.
- Real-time speech recognition with Dragon Bar: Dictate directly into applications for convenience, such as Word documents or Client Management Systems (CMS), simplifying the documentation process.
- Data Security: Philips SpeechLive prioritizes data security, with servers located in five regions worldwide and features such as Multifactor Authentication and Single Sign-on.
In the legal profession, effective communication requires reliance on and integration of precise speech recognition and a seamlessly integrated workflow system.
Philips SpeechLive platform's versatility and convenience cater to the dynamic needs of legal professionals. This all-in-one dictation and transcription platform empowers time-pressed professionals and high-demand firms to save time and earn more money by automating the documentation process between authors and transcriptionists, also allowing them to work flexibly from anywhere.
Free demos of Philips SpeechLive with Nuance Dragon integration are available at www.speechlive.com/dragon-speech-recognition.
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410464123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom